Lv11
60 积分 2025-07-17 加入
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens
1小时前
已完结
Recurrent DDX41 mutation in very late relapse after allogeneic stem cell transplantation
1小时前
已完结
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study
2小时前
求助中
Spliceosomal GTPase EFTUD2 mediates DDX41 intron retention to promote the malignant progression of ovarian cancer
3个月前
已完结
Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding
3个月前
已关闭
Menin inhibitors seek to debut as newest targeted therapy for leukaemia
3个月前
已关闭
Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia
4个月前
已完结
A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations
4个月前
已完结
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
4个月前
已关闭
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
4个月前
已关闭
皖公网安备34019202002308
